Repligen (RGEN)

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

De Repligen Corporation Common Stock (RGEN) aandelenkoers vandaag is , wat een NaN% beweging weergeeft sinds de markt geopend. De marktkapitalisatie van het bedrijf staat op $ 7,03 mld., met een dagelijks tradevolume van aandelen. De vorige slotkoers was .

Klaar om aan de slag te gaan? Volg de onderstaande stappen, of lees onze gids over hoe je Repligen aandelen op Kraken kunt kopen vanaf € 10.